Overall, when using the full panel of tau antibodies (ie AT8, pThr175 and pThr217 antibodies), 17 (41 %) patients with MND (patients #1–17), 9 (56 %) patients with FTD + MND (patients #42–50) and 13 (56 %) patients with FTD alone (patients #58–70) showed either no tau pathology at all, or only isolated neuronal tau pathology, in any region of brain examined. This evidence concerns the gene MAPT and mild neurocognitive disorder.